Literature DB >> 34722721

Targeting the Intestinal Barrier to Prevent Gut-Derived Inflammation and Disease: A Role for Intestinal Alkaline Phosphatase.

Florian Kühn1, Ruifeng Duan1, Matthias Ilmer1, Ulrich Wirth1, Fatemeh Adiliaghdam2, Tobias S Schiergens1, Joachim Andrassy1, Alexandr V Bazhin1, Jens Werner1.   

Abstract

BACKGROUND: Intestinal alkaline phosphatase (IAP) as a tissue-specific isozyme of alkaline phosphatases is predominantly produced by enterocytes in the proximal small intestine. In recent years, an increasing number of pathologies have been identified to be associated with an IAP deficiency, making it very worthwhile to review the various roles, biological functions, and potential therapeutic aspects of IAP.
SUMMARY: IAP primarily originates and acts in the intestinal tract but affects other organs through specific biological axes related to its fundamental roles such as promoting gut barrier function, dephosphorylation/detoxification of lipopolysaccharides (LPS), and regulation of gut microbiota. KEY MESSAGES: Numerous studies reporting on the different roles and the potential therapeutic value of IAP across species have been published during the last decade. While IAP deficiency is linked to varying degrees of physiological dysfunctions across multiple organ systems, the supplementation of IAP has been proven to be beneficial in several translational and clinical studies. The increasing evidence of the salutary functions of IAP underlines the significance of the naturally occurring brush border enzyme.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Diabetes; Endotoxemia; Gut barrier; Intestinal alkaline phosphatase; Lipopolysaccharides; Metabolic syndrome; Microbiome

Year:  2021        PMID: 34722721      PMCID: PMC8543353          DOI: 10.1159/000515910

Source DB:  PubMed          Journal:  Visc Med        ISSN: 2297-4725


  77 in total

Review 1.  The life and death of epithelia during inflammation: lessons learned from the gut.

Authors:  Stefan Koch; Asma Nusrat
Journal:  Annu Rev Pathol       Date:  2011-08-12       Impact factor: 23.472

2.  Prevention of antibiotic-associated metabolic syndrome in mice by intestinal alkaline phosphatase.

Authors:  K P Economopoulos; N L Ward; C D Phillips; A Teshager; P Patel; M M Mohamed; S Hakimian; S B Cox; R Ahmed; O Moaven; K Kaliannan; S N Alam; J F Haller; A M Goldstein; A K Bhan; M S Malo; R A Hodin
Journal:  Diabetes Obes Metab       Date:  2016-03-22       Impact factor: 6.577

3.  Exogenous alkaline phosphatase treatment complements endogenous enzyme protection in colonic inflammation and reduces bacterial translocation in rats.

Authors:  P Martínez-Moya; M Ortega-González; R González; A Anzola; B Ocón; C Hernández-Chirlaque; R López-Posadas; M D Suárez; A Zarzuelo; O Martínez-Augustin; F Sánchez de Medina
Journal:  Pharmacol Res       Date:  2012-05-05       Impact factor: 7.658

Review 4.  Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure.

Authors:  Hiroshi Fukui
Journal:  Alcohol Clin Exp Res       Date:  2005-11       Impact factor: 3.455

Review 5.  Interplay between intestinal alkaline phosphatase, diet, gut microbes and immunity.

Authors:  Mehrbod Estaki; Daniella DeCoffe; Deanna L Gibson
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

6.  Prophylactic treatment with alkaline phosphatase in cardiac surgery induces endogenous alkaline phosphatase release.

Authors:  Suzanne Kats; Ruud Brands; Mohamed A Soliman Hamad; Willem Seinen; Volkher Scharnhorst; Raymond W Wulkan; Jacques P Schönberger; Wim van Oeveren
Journal:  Int J Artif Organs       Date:  2012-02       Impact factor: 1.595

7.  Effects of a human recombinant alkaline phosphatase during impaired mitochondrial function in human renal proximal tubule epithelial cells.

Authors:  Esther Peters; Tom Schirris; Alexander H van Asbeck; Jelle Gerretsen; Jennifer Eymael; Angel Ashikov; Merel J W Adjobo-Hermans; Frans Russel; Peter Pickkers; Rosalinde Masereeuw
Journal:  Eur J Pharmacol       Date:  2016-12-22       Impact factor: 4.432

8.  Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis.

Authors:  Milan Lukas; Pavel Drastich; Michal Konecny; Paolo Gionchetti; Ondrej Urban; Franco Cantoni; Martin Bortlik; Dana Duricova; Michael Bulitta
Journal:  Inflamm Bowel Dis       Date:  2010-07       Impact factor: 5.325

9.  Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphatase.

Authors:  Esther Peters; Jasper Stevens; Jacques Arend; Zheng Guan; Willem Raaben; Peter Laverman; Andrea van Elsas; Rosalinde Masereeuw; Peter Pickkers
Journal:  Int J Pharm       Date:  2015-09-07       Impact factor: 5.875

Review 10.  Mechanisms regulating intestinal barrier integrity and its pathological implications.

Authors:  Chaithanya Chelakkot; Jaewang Ghim; Sung Ho Ryu
Journal:  Exp Mol Med       Date:  2018-08-16       Impact factor: 8.718

View more
  1 in total

1.  Intestinal alkaline phosphatase (IAP, IAP Enhancer) attenuates intestinal inflammation and alleviates insulin resistance.

Authors:  Chenzhe Gao; Marwa Yagoub Farag Koko; Mingxing Ding; Weichen Hong; Jianping Li; Na Dong; Mizhou Hui
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.